Health ProductsPublic Communication

Mesna (Uromitexan), Multi-Dose Vials - Association with Fatal Gasping Syndrome in Neonates and Infants - For the Public

· Published by Health Canada · Official notice

Details

Alert type: Public Communication
Category: Drugs, Affects children, pregnant or breast feeding women
Audience: General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Baxter Corporation.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories



Public Communication - Health Canada Endorsed Important Safety Information on UROMITEXAN (Mesna Injection) 100mg/mL

August 15, 2011

Subject: Association of mesna (Uromitexan), multi-dose vials with fatal gasping syndrome in children

This letter is being sent out following consultation with Health Canada regarding mesna (Uromitexan) multi-dose vials which was recently approved in Canada. Baxter Corporation is issuing this letter to ensure that prescribers have the most recent information available when considering mesna (Uromitexan) as a treatment option in the prevention of blood in urine.

Mesna (Uromitexan), multi-dose vials is indicated for the reduction and prevention of bleeding from the bladder caused by the treatment with a group of drugs called oxazaphosphorines (such as Ifosfamide, Glufosfamide and Cyclophosphamide).

  • Mesna (Uromitexan), multi-dose vials is indicated for use in adults and children 13 years and older only. However, this product has been reported to be used off-label in younger patients.
  • There have been reported cases of a fatal respiratory syndrome in children associated with the use of drugs containing the preservative benzyl alcohol.
  • Prescribers have been advised to use this product as per its approved use.

To read the full content of the Dear Health Professional Letter (DHPL) for Mesna (UROMITEXAN), Multi-Dose Vials - Association with Fatal Gasping Syndrome in Neonates and Infants - For Health Professionals.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of fatal or life-threatening respiratory syndrome or other serious or unexpected adverse reactions in patients receiving UROMITEXAN should be reported to Baxter Corporation or Health Canada.

Baxter Corporation,
Mississauga, Ontario
1-888-719-9955

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

  • Report online at MedEffect™ Canada
  • Call toll-free at 1-866-234-2345
  • Complete a Reporting Form and:
    • Fax toll-free to 1-866-678-6789, or
    • Mail to: Canada Vigilance Program Health Canada
      Postal Locator 0701E
      K1A 0K9

The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction and Medical Device Problem Reporting section.

For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738

Sincerely,

original signed by

Adel Gehchan, MD
Director, Medical and Clinical Affairs
Baxter Corporation



References:

  1. Product Monograph, PrUROMITEXAN (mesna Injection) 100mg/mL, August 2011
  2. Promoting Safety of Medicine for Children (Download PDF document)
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime